Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

November 14, 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

November 11, 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

November 09, 2023

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

News Conference News AHA 2020

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

November 18, 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

November 15, 2020

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

November 19, 2019

More Adverse Events, Higher Costs With Impella: New Observational Studies

News Conference News AHA 2019

More Adverse Events, Higher Costs With Impella: New Observational Studies

November 17, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

News Conference News AHA 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.